CC BY-NC-ND 4.0 · Exp Clin Endocrinol Diabetes Rep 2018; 05(01): e9-e12
DOI: 10.1055/a-0630-0412
Case Report
Eigentümer und Copyright ©Georg Thieme Verlag KG 2018

Case Report: Persistent Acromegaly – Effective Therapy with Lanreotide and Weekly Pegvisomant Injections

Thomas H. Schürmeyer
1  Klinikum Mutterhaus der Borromäerinnen, Department of Endocrinology, Trier, Germany
,
Britta Galling
2  Charité Universitätsmedizin, Department of Child and Adolescent Psychiatry, Berlin, Germany
3  The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York, USA
4  Hofstra Northwell School of Medicine at Hofstra University, Hempstead, New York, USA
› Author Affiliations
Further Information

Publication History

received 23 March 2018
revised 30 April 2018

accepted 09 May 2018

Publication Date:
11 June 2018 (online)

Abstract

Objective Therapeutic options for persistent acromegaly after surgery include another surgical approach, radiotherapy, medical therapy or a combination of these procedures. We describe a patient with persistent acromegaly despite heavy pre-treatment who was in need of a simplified mode of effective therapy.

Methods In a 45-year old patient after transsphenoidal pituitary surgery followed by linear accelerator irradiation of the residual tumor two years later acromegaly could not be controlled by a tolerable dosage of intramuscular octreotide LAR. For professional reasons the patient requested a simplified mode of treatment.

Results In order to improve efficacy and treatment convenience, we combined subcutaneous injections of lanreotide up to 120 mg monthly performed by the patient’s spouse and of pegvisomant 80 mg weekly conducted by the patient himself. This therapy was well tolerated and satisfactory endocrine control was achieved. Magnetic resonance imaging did not show any remaining tumor within a year. 5 years following surgery and 3 years following irradiation pegvisomant could be stopped and levels of insulin growth factor 1 and growth hormone remained in the normal range. The interval of lanreotide given subcutaneously by the patient’s spouse could be extended stepwise and somatostatin analog treatment was terminated after 7.5 years when the patient was cured.

Conclusions Excessive growth hormone secretion persisting after pituitary surgery and irradiation can be controlled in a convenient way for the patient with acromegaly by combining monthly lanreotide and weekly pegvisomant injections, if monotherapy with a somatostatin analog fails.